tafasitamab + lenalidomide + parsaclisib + R-CHOP
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Hodgkins Lymphoma
Conditions
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
Trial Timeline
Dec 15, 2020 → Dec 31, 2026
NCT ID
NCT04661007About tafasitamab + lenalidomide + parsaclisib + R-CHOP
tafasitamab + lenalidomide + parsaclisib + R-CHOP is a phase 1/2 stage product being developed by Incyte for Non Hodgkins Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04661007. Target conditions include Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma.
Hype Score Breakdown
Clinical
9
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04661007 | Phase 1/2 | Active |
Competing Products
18 competing products in Non Hodgkins Lymphoma